Fundraising Fox
Progentec
Oklahoma City, US · Founded 2015 · Delaware corporation · 16 employees on LinkedIn · 10 known investors
Find your way into Progentec
Sign up to see every warm intro you have to Progentec
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Progentec team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Progentec develops diagnostic and digital health solutions for autoimmune disease detection and treatment, including biomarker tests and remote monitoring technologies for clinicians and patients. The company focuses on improving health outcomes for the 25 million Americans living with autoimmune diseases.
Founders & leadership
Investors · 10
Also in the syndicate · 6
Funding
SEC filings, press & company announcements$7.5M disclosed across 2 rounds · 2017–2020
- $5MSeries AJan 2020 · 2 sources
Plains Venture Partners (lead), the Oklahoma Angel Capital Fund II (lead), the Oklahoma Seed Capital Fund (lead), Burns & Stowers Investments LLC, i2E Management Company, Mayo Clinic, NMC Health, OCA Ventures, Stanford University, the Oklahoma Medical Research Foundation
Source ↗
▶$2.5MraisedNov 2018 · 7 investors · BiotechnologyRule 506(c)
- Robert SaundersDirector
- Mohan PurushothamanExecutive Officer, Director
- Sanjiv SharmaExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Minimum investment
- $75K
- Proceeds to insiders
- $150K
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Progentec.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Progentec do?
- Progentec develops diagnostic and digital health solutions for autoimmune disease detection and treatment, including biomarker tests and remote monitoring technologies for clinicians and patients. The company focuses on improving health outcomes for the 25 million Americans living with autoimmune diseases.
- Who are Progentec's investors?
- Progentec's investors include Plains Ventures, Mayo Clinic Ventures, OCA Ventures, Stanford University.
- How much funding has Progentec raised?
- Progentec has disclosed $7.5M raised across 2 rounds.
- Where is Progentec headquartered?
- Progentec is headquartered in Oklahoma City, US.